The “Hepatitis C – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Hepatitis C pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Hepatitis C R&D. The therapies under development are focused on novel approaches to treat/improve Hepatitis C.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Hepatitis C Emerging Drugs Chapters
This segment of the Hepatitis C report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Hepatitis C Emerging Drugs
TG-2349: Dongguan HEC TaiGen Biopharmaceuticals
TG-2349 (Furaprevir) is a HCV protease inhibitor. It is a novel direct acting antivirals for the all-oral treatment of chronic hepatitis C virus (HCV) infection. The drug has completed Phase III clinical evaluation in combination with DAG181 and Ribavirin for 12 weeks of treatment in HCV Genotype I Infected patients.
SH229: Nanjing Sanhome Pharmaceutical
SH229 is a NS5B inhibitor that is being developed by Nanjing Sanhome Pharmaceutical for the treatment of chronic hepatitis C virus infection. The drug is currently in Phase II/III clinical studies combined with fixed-dose Daclatasvi dihydrochloride (DCV) tablets for the treatment of hepatitis C virus infection.
Hepatitis C: Therapeutic Assessment
This segment of the report provides insights about the different Hepatitis C drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Hepatitis C
There are approx. 70+ key companies which are developing the therapies for Hepatitis C. The companies which have their Hepatitis C drug candidates in the most advanced stage, i.e. Phase III include, Dongguan HEC TaiGen Biopharmaceuticals.
Hepatitis C: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hepatitis C therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hepatitis C drugs.
Hepatitis C Report Insights
- Hepatitis C Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Hepatitis C Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Source: Business Wire